Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Trygve Holmøy, Øivind Torkildsen & Kjell-Morten Myhr. (2017) An update on cladribine for relapsing-remitting multiple sclerosis. Expert Opinion on Pharmacotherapy 18:15, pages 1627-1635.
Read now
Read now
Emanuele D’Amico, Carmela Leone, Cinzia Caserta & Francesco Patti. (2015) Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Review of Neurotherapeutics 15:7, pages 803-824.
Read now
Read now
Jan Thöne & Gisa Ellrichmann. (2013) Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug, Healthcare and Patient Safety 5, pages 37-47.
Read now
Read now
Giancarlo Comi, Hans-Peter Hartung, Nuwan C Kurukulasuriya, Steven J Greenberg & Matthew Scaramozza. (2013)
Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis. Expert Opinion on Pharmacotherapy 14:1, pages 123-136.
Read now
Read now
Kenneth P Johnson. (2010) Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Therapeutics and Clinical Risk Management 6, pages 153-172.
Read now
Read now
Julie A Murphy, Jacklyn A Harris & Andrew J Crannage. (2010) Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. Neuropsychiatric Disease and Treatment 6, pages 619-625.
Read now
Read now
Rina Aharoni. (2010) Immunomodulatory drug treatment in multiple sclerosis. Expert Review of Neurotherapeutics 10:9, pages 1423-1436.
Read now
Read now
Mathias Buttmann. (2010) Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Review of Neurotherapeutics 10:5, pages 791-809.
Read now
Read now
Jack C Sipe. (2010) Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Expert Review of Neurotherapeutics 10:3, pages 365-375.
Read now
Read now
Darren S Sigal & Alan Saven. (2008) Cladribine in indolent non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 8:4, pages 535-545.
Read now
Read now
Thomas P. Leist & Patrick Vermersch. (2007) The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Current Medical Research and Opinion 23:11, pages 2667-2676.
Read now
Read now
Richard E Gonsette. (2007) Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. Expert Opinion on Pharmacotherapy 8:8, pages 1103-1116.
Read now
Read now
Mark S Freedman. (2006) Disease-modifying drugs for multiple sclerosis: current and future aspects. Expert Opinion on Pharmacotherapy 7:sup1, pages S1-S9.
Read now
Read now
Articles from other publishers (53)
Jasem Al-Hashel, Samar Farouk Ahmed, Malak AlMojel & Raed Alroughani. (2023) A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine. Clinical Neurology and Neurosurgery 232, pages 107885.
Crossref
Crossref
Fardin Nabizadeh, Mobin Mohamadi, Shayan Rahmani, Rayan Rajabi, Fatemeh Afrashteh, Soroush Najdaghi & Omid Mirmosayyeb. (2023) Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis. Neurological Sciences 44:9, pages 3045-3057.
Crossref
Crossref
Hussein Baharlooi, Amir Hossein Mansourabadi, Moein Minbashi Moeini, Leila Mohamed Khosroshahi & Maryam Azimi. (2021) Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression. Cellular and Molecular Neurobiology 42:8, pages 2611-2627.
Crossref
Crossref
Syed Saqib Ali, Ruchika Raj, Tejinder Kaur, Brenna Weadick, Debasis Nayak, Minnsung No, Jane Protos, Hannah Odom, Kajal Desai, Avinash K. Persaud, Joanne Wang & Rajgopal Govindarajan. (2022) Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective. Cancers 14:13, pages 3113.
Crossref
Crossref
Kottil Rammohan, Patricia K. Coyle, Elke Sylvester, Andrew Galazka, Fernando Dangond, Megan Grosso & Thomas P. Leist. (2020) The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review. Drugs 80:18, pages 1901-1928.
Crossref
Crossref
Yamel Rito, Verónica Rivas-Alonso & Erwin Chiquete. (2020) Cladribina para el tratamiento de la esclerosis múltiple remitente recurrente: nueva alternativa para Latinoamérica. Latin american journal of clinical sciences and medical technology 2:2, pages 97-105.
Crossref
Crossref
Francesco Aruta, Aniello Iovino, Claudia Costa, Fiore Manganelli & Rosa Iodice. (2020) Lichenoid rash: A new side effect of oral Cladribine. Multiple Sclerosis and Related Disorders 41, pages 102023.
Crossref
Crossref
Nora Möhn, Thomas Skripuletz, Kurt-Wolfram Sühs, Sylvia Menck, Elke Voß & Martin Stangel. (2019) Therapy with cladribine is efficient and safe in patients previously treated with natalizumab. Therapeutic Advances in Neurological Disorders 12, pages 175628641988759.
Crossref
Crossref
Mark S. Freedman, Daniel Selchen, Alexandre Prat & Paul S. Giacomini. (2018) Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 45:5, pages 489-503.
Crossref
Crossref
Serkan Yavuz, Aysu Çetin, Atilla Akdemir, Doğukan Doyduk, Ali Dişli, Gurbet Çelik Turgut, Alaattin Şen & Yılmaz Yıldırır. (2017) Synthesis and Functional Investigations of Computer Designed Novel Cladribine-Like Compounds for the Treatment of Multiple Sclerosis. Archiv der Pharmazie 350:11, pages 1700185.
Crossref
Crossref
Gavin Giovannoni. (2017) Cladribine to Treat Relapsing Forms of Multiple Sclerosis. Neurotherapeutics 14:4, pages 874-887.
Crossref
Crossref
Erick W. Co & Julian P. Henschke. 2016. Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 2. Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 2
271
321
.
C.D. De Gasperis-Brigante, J.L. Parker, P.W. O’Connor & T.R. Bruno. (2016) Reducing clinical trial risk in multiple sclerosis. Multiple Sclerosis and Related Disorders 5, pages 81-88.
Crossref
Crossref
Eric M. Williamson & Joseph R. Berger. (2015) Infection Risk in Patients on Multiple Sclerosis Therapeutics. CNS Drugs 29:3, pages 229-244.
Crossref
Crossref
Stefan H.P. Kraus, Felix Luessi, Bettina Trinschek, Steffen Lerch, Mario Hubo, Laura Poisa-Beiro, Magdalena Paterka, Helmut Jonuleit, Frauke Zipp & Valérie Jolivel. (2014) Cladribine exerts an immunomodulatory effect on human and murine dendritic cells. International Immunopharmacology 18:2, pages 347-357.
Crossref
Crossref
Paul W. O’Connor & Jiwon Oh. 2014. Multiple Sclerosis and Related Disorders. Multiple Sclerosis and Related Disorders
465
501
.
Krystyna Mitosek-Szewczyk, Jacek Tabarkiewicz, Barbara Wilczynska, Katarzyna Lobejko, Jerzy Berbecki, Marcin Nastaj, Ewa Dworzanska, Beata Kolodziejczyk, Zbigniew Stelmasiak & Jacek Rolinski. (2013) Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis. Journal of the Neurological Sciences 332:1-2, pages 35-40.
Crossref
Crossref
Vikramjeet Singh, Elke Verena Voss, Karelle Bénardais & Martin Stangel. (2012) Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia. Journal of Neuroimmune Pharmacology 7:4, pages 939-950.
Crossref
Crossref
Alfred W. Sandrock & Richard A. Rudick. 2012. Translational Neuroscience. Translational Neuroscience
178
196
.
Shiv Saidha, Christopher Eckstein & Peter A. Calabresi. (2012) New and emerging disease modifying therapies for multiple sclerosis. Annals of the New York Academy of Sciences 1247:1, pages 117-137.
Crossref
Crossref
Gavin Giovannoni & Stuart D. Cook. 2011. Multiple Sclerosis Therapeutics. Multiple Sclerosis Therapeutics
358
369
.
. 2011. Multiple Sclerosis Therapeutics. Multiple Sclerosis Therapeutics
300
582
.
Colleen E. Miller & Margaret A. Umhauer. (2011) Emerging Oral Therapies for Multiple Sclerosis. Journal of Neuroscience Nursing 43:1, pages 3-14.
Crossref
Crossref
Francesca BagnatoIstvan Pirko. (2011) Novel Agents and Emerging Treatment Strategies in Multiple Sclerosis. What Role for Cladribine?. Clinical Medicine Insights: Therapeutics 3, pages CMT.S6456.
Crossref
Crossref
Ralf Gold. (2011) Oral Therapies for Multiple Sclerosis. CNS Drugs 25:1, pages 37-52.
Crossref
Crossref
Thomas P. Leist & Robert Weissert. (2011) Cladribine. Clinical Neuropharmacology 34:1, pages 28-35.
Crossref
Crossref
Amy Perrin Ross & Ben W. Thrower. (2010) Recent Developments in the Early Diagnosis and Management of Multiple Sclerosis. Journal of Neuroscience Nursing 42:6, pages 342-353.
Crossref
Crossref
Amer M. Awad & Olaf Stüve. (2010) IMMUNOPATHOGENESIS OF MULTIPLE SCLEROSIS. CONTINUUM: Lifelong Learning in Neurology 16, pages 166-180.
Crossref
Crossref
S. Schmidt. (2010) Cladribin-Tabletten bei schubförmiger Multipler SkleroseOral cladribine for relapsing-remitting multiple sclerosis. Der Nervenarzt 81:10, pages 1231-1241.
Crossref
Crossref
Bernd C. KieseierDouglas R. Jeffery. (2010) Chemotherapeutics in the treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders 3:5, pages 277-291.
Crossref
Crossref
William M. Carroll. (2010) Oral Therapy for Multiple Sclerosis — Sea Change or Incremental Step?. New England Journal of Medicine 362:5, pages 456-458.
Crossref
Crossref
H.-P. Hartung, B.C. Kieseier & O. Aktas. (2010) CladribinCladribin. Der Nervenarzt 81:2, pages 194-202.
Crossref
Crossref
Michael NamakaChristine Leong, Michael Prout, Josee-Anne Le Dorze, Mike LimerickEmma Frost & Farid Esfahani. (2010) Emerging Therapies for the Management of Multiple Sclerosis. Clinical Medicine Insights: Therapeutics 2, pages CMT.S2213.
Crossref
Crossref
Heinz Wiendl, Nico Melzer, Christoph Kleinschnitz & Sven G. Meuth. 2010. MULTIPLE SCLEROSIS 3. MULTIPLE SCLEROSIS 3
388
426
.
J.N. Latosińska, M. Latosińska, J. Seliger, V. Žagar & Z. Kazimierczuk. (2009) Electron density distribution in cladribine (2-chloro-2′-deoxyadenosine) – A drug against leukemia and multiple sclerosis – Studied by multinuclear NQR spectroscopy and DFT calculations. Chemical Physics Letters 476:4-6, pages 293-302.
Crossref
Crossref
Sven G. Meuth, Stefan Bittner & Heinz Wiendl. (2014) Immunotherapy of multiple sclerosis. Acta Neuropsychiatrica 21:S2, pages 27-34.
Crossref
Crossref
Jeffrey L. Bennett & Olaf Stüve. (2009) Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis. Clinical Neuropharmacology 32:3, pages 121-132.
Crossref
Crossref
T. Kopadze, M. Döbert, V. I. Leussink, T. Dehmel & B. C. Kieseier. (2009)
Cladribine impedes
in vitro
migration of mononuclear cells: a possible implication for treating multiple sclerosis
. European Journal of Neurology 16:3, pages 409-412.
Crossref
Crossref
Hans-Peter Hartung. (2009) New oral therapies may offer improved treatment options for patients with multiple sclerosis. Current Opinion in Neurology 22:Suppl 1, pages S10-S14.
Crossref
Crossref
Sven G. Meuth, Christoph Kleinschnitz & Heinz Wiendl. (2008) Recent clinical trials and future therapies. Journal of Neurology 255:S6, pages 93-96.
Crossref
Crossref
Peter Rieckmann, Anthony Traboulsee, Virginia Devonshire & Joel Oger. (2008) Review: Escalating immunotherapy of multiple sclerosis. Therapeutic Advances in Neurological Disorders 1:3, pages 181-192.
Crossref
Crossref
Ralf A. Linker, Bernd C. Kieseier & Ralf Gold. (2008) Identification and development of new therapeutics for multiple sclerosis. Trends in Pharmacological Sciences 29:11, pages 558-565.
Crossref
Crossref
Kathleen Costello & Jack C. Sipe. (2008) Cladribine Tabletsʼ Potential in Multiple Sclerosis Treatment. Journal of Neuroscience Nursing 40:5, pages 275-280.
Crossref
Crossref
H. Wiendl, K. V. Toyka, P. Rieckmann, R. Gold, H.-P. Hartung & R. Hohlfeld. (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. Journal of Neurology 255:10, pages 1449-1463.
Crossref
Crossref
B. A. Cohen & P. Rieckmann. (2007) Emerging oral therapies for multiple sclerosis. International Journal of Clinical Practice 61:11, pages 1922-1930.
Crossref
Crossref
Oliver Neuhaus, Bernd C. Kieseier & Hans-Peter Hartung. (2007) Immunosuppressive agents in multiple sclerosis. Neurotherapeutics 4:4, pages 654-660.
Crossref
Crossref
C. Kleinschnitz, S.G. Meuth, B.C. Kieseier & H. Wiendl. (2007) Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen AnsätzenUpdate on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis. Der Nervenarzt 78:8, pages 883-911.
Crossref
Crossref
J. E. Martinez-Rodriguez, D. Cadavid, L. J. Wolansky, L. Pliner & S. D. Cook. (2007) Cladribine in aggressive forms of multiple sclerosis. European Journal of Neurology 14:6, pages 686-689.
Crossref
Crossref
William R. Hartman, D. Eric Walters & Patricia Hentosh. (2007) Presence of the anti-leukemic nucleotide analog, 2-chloro-2′-deoxyadenosine-5′-monophosphate, in a promoter sequence alters DNA binding of TATA-binding protein (TBP). Archives of Biochemistry and Biophysics 459:2, pages 223-232.
Crossref
Crossref
Bernd C Kieseier & Heinz Wiendl. (2007) Oral Disease-Modifying Treatments for Multiple Sclerosis. CNS Drugs 21:6, pages 483-502.
Crossref
Crossref
Heinz Wiendl & Reinhard Hohlfeld. 2007. Immune Regulation and Immunotherapy in Autoimmune Disease. Immune Regulation and Immunotherapy in Autoimmune Disease
289
338
.
Peter Rieckmann. (2006) Immunmodulatorische Stufentherapie der Multiplen SkleroseEscalating immunomodulatory therapy of multiple sclerosis. Der Nervenarzt 77:12, pages 1506-1518.
Crossref
Crossref
Julie A Brousil, Russel J Roberts & Amanda L Schlein. (2016) Cladribine: An Investigational Immunomodulatory Agent for Multiple Sclerosis. Annals of Pharmacotherapy 40:10, pages 1814-1821.
Crossref
Crossref